Your browser doesn't support javascript.
loading
A Straightforward Approach to Synthesize 7-Aminocephalosporanic Acid In Vivo in the Cephalosporin C Producer Acremonium chrysogenum.
Lin, Xuemei; Lambertz, Jan; Dahlmann, Tim A; Nowaczyk, Marc M; König, Burghard; Kück, Ulrich.
Afiliación
  • Lin X; Allgemeine und Molekulare Botanik, Ruhr-Universität Bochum, 44780 Bochum, Germany.
  • Lambertz J; Plant Biochemistry, Ruhr-University Bochum, 44780 Bochum, Germany.
  • Dahlmann TA; Allgemeine und Molekulare Botanik, Ruhr-Universität Bochum, 44780 Bochum, Germany.
  • Nowaczyk MM; Plant Biochemistry, Ruhr-University Bochum, 44780 Bochum, Germany.
  • König B; Koenig und Funk Biotech GmbH, 13156 Berlin, Germany.
  • Kück U; Allgemeine und Molekulare Botanik, Ruhr-Universität Bochum, 44780 Bochum, Germany.
J Fungi (Basel) ; 8(5)2022 Apr 26.
Article en En | MEDLINE | ID: mdl-35628706
The pharmaceutical industry has developed various highly effective semi-synthetic cephalosporins, which are generated by modifying the side chains of the core molecule 7-aminocephalosporanic acid (7-ACA). In industrial productions, the 7-ACA nucleus is obtained in vitro from cephalosporin C (CPC) by chemical or enzymatic processes, which are waste intensive and associated with high production costs. Here, we used a transgenic in vivo approach to express bacterial genes for cephalosporin C acylase (CCA) in the CPC producer Acremonium chrysogenum. Western blot and mass spectrometry analyses verified that the heterologous enzymes are processed into α- and ß-subunits in the fungal cell. Extensive HPLC analysis detected substrates and products of CCAs in both fungal mycelia and culture supernatants, with the highest amount of 7-ACA found in the latter. Using different incubation times, temperatures, and pH values, we explored the optimal conditions for the active bacterial acylase to convert CPC into 7-ACA in the culture supernatant. We calculated that the best transgenic fungal strains exhibit a one-step conversion rate of the bacterial acylase of 30%. Our findings can be considered a remarkable contribution to supporting future pharmaceutical manufacturing processes with reduced production costs.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Fungi (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Fungi (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Suiza